The Ketamine Clinic Craze: Legalities and Possibilities

In recent years, the United States has seen a proliferation of ketamine clinics. From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. In an even larger trend, the health care provider

Ketamine Due Diligence: What Any Buyer Should Know – Part 1

We have worked on several ketamine acquisitions, and one of the most important aspects of any deal is due diligence. Shortly after term sheets or letters of intent are executed, most buyers send out a due diligence request list to the seller. This post will focus on the healthcare regulatory issues a buyer will want

Ketamine Clinics and the Corporate Practice of Medicine in California

Ketamine clinics are increasing in number in the United States and globally. As we described previously, ketamine is a Schedule III drug under the federal Controlled Substances Act, has been approved by the Food and Drug Administration (FDA) for certain medical uses, and may in some cases be used for off-label uses (such as anxiety

Ketamine Management Services Organizations (MSOs): The California Puzzle

Our law firm has seen an uptick in ketamine clients lately. And it’s no surprise as the drug picks up considerable speed with its off-label infusion applications for a slew of serious ailments, including depression and mood disorders. We’ve also been handling several M&A deals around ketamine clinics and the management companies that serve them.

Ketamine Due Diligence: What Any Buyer Should Know, Part 2

As noted in Ketamine Due Diligence: What A Buyer Should Know – Part 1, we have worked on several Ketamine clinic acquisitions, and one of the most important aspects of any deal is due diligence. This post will discuss some of the state healthcare regulatory issues a buyer will want to focus on for a

FREE Webinar Tomorrow: Ketamine, Psilocybin and New Drug Therapies

Watch the webinar HERE! For the last 10 years, Harris Bricken attorneys have counseled countless domestic and international businesses and entrepreneurs on rapidly evolving laws and regulations in the cannabis, hemp, and cannabidiol (CBD) industries. As the legal and regulatory frameworks of those industries begin to solidify, new opportunities are emerging for the commercialization and

FREE Webinar: Ketamine, Psilocybin and New Drug Therapies

Watch the webinar HERE! For the last 10 years, Harris Bricken attorneys have counseled countless domestic and international businesses and entrepreneurs on rapidly evolving laws and regulations in the cannabis, hemp, and cannabidiol (CBD) industries. As the legal and regulatory frameworks of those industries begin to solidify, new opportunities are emerging for the commercialization and

FREE Webinar: Ketamine, Psilocybin and New Drug Therapies

Watch the webinar HERE! For the last 10 years, Harris Bricken attorneys have counseled countless domestic and international businesses and entrepreneurs on rapidly evolving laws and regulations in the cannabis, hemp, and cannabidiol (CBD) industries. As the legal and regulatory frameworks of those industries begin to solidify, new opportunities are emerging for the commercialization and